Nymox Pharmaceutical Corp Recommendation mean
What is the Recommendation mean of Nymox Pharmaceutical Corp?
The Recommendation mean of Nymox Pharmaceutical Corp is N/A
What is the definition of Recommendation mean?
Recommendation mean is the mean of analysts’ ratings of the stock ranging from 1.0 (strong buy) to 5.0 (strong sell).
Mean of recommendations is an average of ratings from different analysts but it should still be used with other research and investment metrics in order to make investment decisions. It is important to understand a firm's entire scale when assimilating ratings. Additionally, analyst recommendations on stocks owned by firms employing them may be seen as potentially biased.
Financial analysts are often employed by mutual and pension funds, hedge funds, securities firms, banks, investment banks, insurance companies, and other businesses, helping these companies or their clients make investment decisions. Financial analysts employed in commercial lending perform "balance sheet analysis," examining the audited financial statements and corollary data in order to assess lending risks. In a stock brokerage house or in an investment bank, they read company financial statements and analyze commodity prices, sales, costs, expenses, and tax rates in order to determine a company's value and project future earnings. In any of these various institutions, the analyst often meets with company officials to gain a better insight into a company's prospects and to determine the company's managerial effectiveness.
Usually, financial analysts study an entire industry, assessing current trends in business practices, products, and industry competition. They must keep abreast of new regulations or policies that may affect the industry, as well as monitor the economy to determine its effect on earnings.
What does Nymox Pharmaceutical Corp do?
nymox pharmaceutical corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population. its lead drug candidate is fexapotide triflutate (nx-1207) that has completed phase iii clinical trials for the treatment of benign prostatic hyperplasia; and is in phase ii clinical trial for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. the company also develops and markets nicalert and tobacalert test strips that use urine or saliva to detect use of tobacco products. in addition, it offers alzheimalert, a proprietary urine assay that aids physicians in the diagnosis of alzheimer's disease. the company operates in canada, the united states, europe, and internationally. nymox pharmaceutical corporation was founded in 1989 and is headquartered in nassau, bahamas.